Discussions in Geneva, demonstrations in Delhi: why incentives for drug innovation need reviewing

Drug Discovery Today

Volumn 12, Issue 9-10, 2007, Pages 349-351

  Ford, Nathan ^a   't Hoen, Ellen ^a   von Schoen Angerer, Tido ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE PLUS ZIDOVUDINE; VALGANCICLOVIR;

AFRICAN TRYPANOSOMIASIS; CANCER; CARDIOVASCULAR DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; EDITORIAL; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; NEUROPATHY; PATENT; TECHNOLOGY; VISCERAL LEISHMANIASIS; WORLD HEALTH ORGANIZATION;

DIFFUSION OF INNOVATION; DRUG INDUSTRY; GOVERNMENT REGULATION; HUMANS; INDIA; INTERNATIONAL COOPERATION; JURISPRUDENCE; PATENTS; SWITZERLAND;

EID: 34247464746     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.03.008     Document Type: Editorial

References (19)

1. Pécoul B., et al. Access to essential drugs in poor countries: a lost battle?. JAMA 281 (1999) 361-367
2. World Trade Organization (2001) Declaration on the Trips Agreement and Public Health, WTO http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm .
3. Supakankunti S., et al. Impact of the World Trade Organization TRIPS Agreement on the pharmaceutical industry in Thailand. WHO Bull 79 (2001) 461-470
4. Ford N., et al. Treating HIV in the developing world: getting ahead of the drug development curve. Drug Discov. Today 12 (2007) 1/2
5. Treerutkuarkul, A. (2007) Ministry pushes ahead with patent breaking. Bangkok Post, 13 February
6. Zamiska, N. (2007) Abbott escalates Thai patent rift. Firm pulls plans to offer new drugs in spat with regime. Wall St. J. 14 March
7. Chirac P., and Torreele E. Global framework on essential health R&D. Lancet 367 (2006) 1560-1561
8. Moran M. Running Out of Breath - TB Care in the 21st Century (2005), Médecins Sans Frontières
9. Veeken H., and Pécoul B. Drugs for 'neglected diseases': a bitter pill. Trop. Med. Int. Health 5 (2000) 309-311
10. Moran, M, et al. (2005) The New Landscape of Neglected Diseases Drug Development, LES/Wellcome Trust (http://www.wellcome.ac.uk/assets/wtx026592.pdf)
11. Anon. A look back at 2000: Overabundance and deregulation. Prescrire Int. 10 (2001) 52-54
12. Morgan S.G., et al. 'Breakthrough' drugs and growth in expenditure on prescription drugs in Canada. Br. Med. J. 331 (2005) 815-881
13. Anon. (1999) Human Development Report, United Nations Development Programme (http://hdr.undp.org/reports/global/1999/en/)
14. Anon. (2006) HIV drug fears. Hundreds rally at Glaxo office. UK firm's move for patent on Combid is 'a threat to access of cheap medicines. Nation, 8 August
15. Ford N., et al. The role of civil society in protecting public health over commercial interests: lessons from Thailand. Lancet 363 (2004) 560-563
16. Mueller J.M. Taking TRIPS to India - Novartis, patent law, and access to medicines. N. Engl. J. Med. 356 (2007) 541-543
17. 't Hoen E. Report of the Commission on Intellectual Property Rights and Health: a call to governments. WHO Bull. 84 (2006) 1-3
18. Stiglitz J. (2006) Give prizes not patents. New Sci. 16 September
19. Anon. (2006) Public Health, Innovation, Essential Health Research and Intellectual Property Rights: Towards a Global Strategy and Plan of Action, World Health Organisation (http://www.who.int/gb/ebwha/pdf_files/WHA59/A59_R24-en.pdf)